Due to maintenance our website might be slower to respond than usual today. We apologise for the inconvenience.
Overview
The marketing authorisation for Thelin has been withdrawn at the request of the marketing authorisation holder.
Thelin : EPAR - Summary for the public
English (EN) (284.21 KB - PDF)
български (BG) (442.17 KB - PDF)
español (ES) (349.5 KB - PDF)
čeština (CS) (345.47 KB - PDF)
dansk (DA) (286.66 KB - PDF)
Deutsch (DE) (351.47 KB - PDF)
eesti keel (ET) (285.38 KB - PDF)
ελληνικά (EL) (388.19 KB - PDF)
français (FR) (348.81 KB - PDF)
italiano (IT) (349.42 KB - PDF)
latviešu valoda (LV) (352.98 KB - PDF)
lietuvių kalba (LT) (316.89 KB - PDF)
magyar (HU) (338.56 KB - PDF)
Malti (MT) (406.16 KB - PDF)
Nederlands (NL) (285.24 KB - PDF)
polski (PL) (346.97 KB - PDF)
português (PT) (348.72 KB - PDF)
română (RO) (376.34 KB - PDF)
slovenčina (SK) (346.2 KB - PDF)
slovenščina (SL) (338.93 KB - PDF)
Suomi (FI) (287.48 KB - PDF)
svenska (SV) (347.88 KB - PDF)
Product information
Thelin : EPAR - Product Information
English (EN) (561.78 KB - PDF)
български (BG) (1.06 MB - PDF)
español (ES) (559.73 KB - PDF)
čeština (CS) (850.38 KB - PDF)
dansk (DA) (579.58 KB - PDF)
Deutsch (DE) (588.47 KB - PDF)
eesti keel (ET) (550.62 KB - PDF)
ελληνικά (EL) (1.09 MB - PDF)
français (FR) (565.06 KB - PDF)
íslenska (IS) (572.14 KB - PDF)
italiano (IT) (582.01 KB - PDF)
latviešu valoda (LV) (872.17 KB - PDF)
lietuvių kalba (LT) (573.31 KB - PDF)
magyar (HU) (874.73 KB - PDF)
Malti (MT) (933.02 KB - PDF)
Nederlands (NL) (565.77 KB - PDF)
norsk (NO) (562.94 KB - PDF)
polski (PL) (881.59 KB - PDF)
português (PT) (577.03 KB - PDF)
română (RO) (551.07 KB - PDF)
slovenčina (SK) (878.03 KB - PDF)
slovenščina (SL) (844.39 KB - PDF)
Suomi (FI) (576.67 KB - PDF)
svenska (SV) (564.5 KB - PDF)
Latest procedure affecting product information: T/0031
06/01/2011
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Thelin : EPAR - All Authorised presentations
English (EN) (212.79 KB - PDF)
български (BG) (302.55 KB - PDF)
español (ES) (212.78 KB - PDF)
čeština (CS) (286.77 KB - PDF)
dansk (DA) (212.72 KB - PDF)
Deutsch (DE) (212.71 KB - PDF)
eesti keel (ET) (212.78 KB - PDF)
ελληνικά (EL) (292.68 KB - PDF)
français (FR) (212.8 KB - PDF)
italiano (IT) (221.33 KB - PDF)
latviešu valoda (LV) (288.52 KB - PDF)
lietuvių kalba (LT) (280.09 KB - PDF)
magyar (HU) (250.21 KB - PDF)
Malti (MT) (310.85 KB - PDF)
Nederlands (NL) (212.59 KB - PDF)
polski (PL) (252.43 KB - PDF)
português (PT) (212.8 KB - PDF)
română (RO) (282.96 KB - PDF)
slovenčina (SK) (285.63 KB - PDF)
slovenščina (SL) (285.94 KB - PDF)
Suomi (FI) (212.69 KB - PDF)
svenska (SV) (212.78 KB - PDF)
Thelin : EPAR - Conditions imposed on member states for safe and effective use - Annex IV
English (EN) (294.19 KB - PDF)
български (BG) (361.79 KB - PDF)
español (ES) (304.05 KB - PDF)
čeština (CS) (329.04 KB - PDF)
dansk (DA) (298.71 KB - PDF)
Deutsch (DE) (305.21 KB - PDF)
eesti keel (ET) (296.51 KB - PDF)
ελληνικά (EL) (366.93 KB - PDF)
français (FR) (303.69 KB - PDF)
italiano (IT) (294.48 KB - PDF)
latviešu valoda (LV) (332.04 KB - PDF)
lietuvių kalba (LT) (305.37 KB - PDF)
magyar (HU) (325.61 KB - PDF)
Malti (MT) (344.82 KB - PDF)
Nederlands (NL) (305.22 KB - PDF)
polski (PL) (337.48 KB - PDF)
português (PT) (299.44 KB - PDF)
română (RO) (301.31 KB - PDF)
slovenčina (SK) (333.66 KB - PDF)
slovenščina (SL) (326.71 KB - PDF)
Suomi (FI) (296.53 KB - PDF)
svenska (SV) (297.57 KB - PDF)
Product details
- Name of medicine
- Thelin
- Active substance
- sitaxentan sodium
- International non-proprietary name (INN) or common name
- sitaxentan sodium
- Therapeutic area (MeSH)
- Hypertension, Pulmonary
- Anatomical therapeutic chemical (ATC) code
- C02KX03
Pharmacotherapeutic group
AntihypertensivesTherapeutic indication
Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.
Authorisation details
- EMA product number
- EMEA/H/C/000679
- Marketing authorisation holder
- Pfizer Ltd.
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom - Marketing authorisation issued
- 10/08/2006
- Revision
- 13
Assessment history
More information on Thelin
This product originally had an orphan designation granted on 21 October 2004. This designation was withdrawn from the Community register of orphan medicinal products in 4 March 2013 upon request of the marketing authorisation holder.
Public statement on Thelin: Withdrawal of the marketing authorisation in the European Union
English (EN) (57.45 KB - PDF)